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ORIGINAL INVESTIGATION

Quality Assessment of a Collaborative Approach
for Decreasing Drug-Related Morbidity
and Achieving Therapeutic Goals
Brian J. Isetts, PhD, BCPS; Lawrence M. Brown, PharmD;
Stephen W. Schondelmeyer, PharmD, PhD; Lois A. Lenarz, MD

Background: Collaboration between physicians and

pharmacists is one approach to address drug-related morbidity and achieve therapeutic goals. A collaborative practice of pharmaceutical care has been used in the Fairview Clinics System of Minneapolis-St Paul since 1999.
Methods: The quality of therapeutic determinations
made by pharmacists within this collaborative practice
of pharmaceutical care was studied by a 12-member panel
of physicians and pharmacists who used randomly selected patient records. This was a quality improvement
and care process validation component of a study evaluating the effects of drug therapy management in patients receiving prepaid medical assistance. An implicit
review process was used to evaluate the clinical credibility of therapeutic determinations made by pharmaceutical care practitioners.
Results: A total of 5780 drug therapy problems were resolved for 2524 patients receiving pharmaceutical care.

The rate of therapeutic goals achieved increased from 74%
at the time of patients’ initial pharmaceutical care encounters to 89% at patients’ latest encounters. In this quality assessment analysis panel members performed a total
of 4779 evaluations of clinical decisions. Panelists indicated agreement with the evaluations in 94.2% of cases,
expressed a neutral opinion in 3.6% of cases, and disagreed in 2.2% of cases. Intraclass correlation coefficients ranged from 0.73 to 0.85.
Conclusions: The decisions made by pharmaceutical care

practitioners working in collaboration with physicians
to provide drug therapy management services are clinically credible based on the evaluations and comments of
a peer review panel. This study provides information on
the quality of care provided by pharmacists when collaborating with physicians to provide drug therapy management services.
Arch Intern Med. 2003;163:1813-1820
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ATIENT SAFETY and quality
improvement in the US
health care system have been
the focus of national reports.1,2 These reports have
called for redesigning the health care system from the perspective of optimizing responsiveness to patients’ needs. When the
needs are related to the use of medications, patients benefit from collaborative
efforts between physicians and pharmacists toward achieving intended goals of
drug therapy while avoiding or minimizing adverse consequences. Several methods of effective collaboration in drug
therapy management have been described.3-5
The collaboration between physicians and pharmacists addresses undesirable and ineffective consequences of medication use. “Drug misadventuring” and
“drug-related morbidity and mortality”
have been used to describe such consequences.6-8 Studies of drug-related mor-
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bidity and mortality have focused on the
incidence of adverse drug events and drug
complications,9-12 characteristics of hospital readmissions, 13 and preventability.9,14 In 1995, the cost impact of these
drug therapy problems in the US health
care system was estimated at $76 billion,
and updated to $177 billion for 2000.8,15
Causes of drug-related morbidity and mortality include acts of commission (ie, prescribing and dispensing drugs, and administering errors), idiosyncratic causes
(ie, unpredictable medication consequences), and acts of omission (ie, absence of systems designed to consistently
help patients achieve desired therapeutic
goals while avoiding or minimizing the adverse consequences of medication use). Although various risk factors have been associated with complications from drug
therapy,16-19 the predictive validity of risk
factors for such problems needs further
study. Undesirable medication-related consequences are not necessarily the fault of
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Table 1. Classification of Drug Therapy Problems*
Indication
1. Additional drug therapy needed
2. Unnecessary drug therapy being used
Effectiveness
3. Ineffective drug therapy
4. Dosage too low
Safety
5. Adverse drug reaction
6. Dosage too high
Convenience
7. Adherence to therapy
*Adapted from Cipolle et al.18

any individual, and they do not constitute a special field
of medicine. Rather, they represent a need to apply theories and approaches already used in other fields to minimize adverse consequences and improve reliability.1
Pharmacists working in collaboration with physicians through a redesigned approach to medication use
can prevent errors and reduce drug costs.20 One of 4 recent suggestions for improving the quality of medication use in elderly patients includes a call for enhanced
collaboration between those who prescribe drugs and
those who know drugs best, ie, clinical pharmacists.21 In
a 2-year study of 397 patients with low- or high-risk coronary heart disease whose pharmacists and physicians
worked persistently and collaboratively to promote adherence with prescribed dyslipidemic therapy, it was
found that, at their last full lipid profile, 62.5% of patients were at or below the low-density lipoprotein cholesterol target levels specified by the National Cholesterol Education Program.22
Drug therapy management and drug management
are terms used in proposed federal legislation and in federal government reports to describe contemporary models in which pharmacists and physicians work together
to manage the complex medication needs of Medicare beneficiaries. A report released by the Medicare Payment Advisory Commission states that “drug management is an
evolving approach to care in which drug therapy decisions are coordinated collaboratively by physicians, pharmacists and other health professionals together with the
patient.” The Medicare Payment Advisory Commission
report also recommends that the Secretary of the US Department of Health and Human Services assess models
for collaborative drug therapy management services in
outpatient settings.23
The impact of pharmacists’ contributions to drug
therapy decision making is found in the literature evaluating the effectiveness of clinical pharmacy services.24,25
A Cochrane database review examining the effects of expanding the roles of ambulatory pharmacists on patient
outcomes and health care use suggests that pharmacist
intervention can improve patient behavior and adherence and improve physician prescribing.26 Studies of pharmacists’ performance in clinical decision making related to the use of medications include a description of
decision-making models,27 factors influencing drug
therapy decision making by pharmacists,28 and decision
analysis applied to clinical pharmacy.29

The term pharmaceutical care was described in the
literature in 1975 as pertaining to the care that a given
patient requires and receives which assures safe and rational drug usage.18,30 An article published in 1990 articulated the responsibilities of a pharmaceutical care practitioner desiring to expand beneficial drug therapy
management services, including the creation of a covenantal bond or therapeutic relationship between patient and pharmacist.31 The practice of pharmaceutical
care is now defined as “a practice in which the practitioner takes responsibility for all of a patient’s drugrelated needs and is held accountable for this commitment.”18
A consistent and systematic pharmaceutical care process is used to (1) assess all of a patient’s drug-related
needs, identify drug therapy problems, and establish therapeutic goals; (2) design a pharmaceutical care plan to help
the patient achieve the established goals and resolve or
prevent drug therapy problems; and (3) conduct follow-up evaluations with the patient to determine progress
toward these goals. A drug therapy problem is defined
as “any aspect of a patient’s drug therapy that is interfering with a desired, positive patient outcome.”18 A classification of drug therapy problems is presented in
Table 1. The practice of pharmaceutical care outlined
in this article encompasses drug therapy management described in proposed federal legislation as well as federal
government reports; therefore, the term drug therapy management is used synonymously with pharmaceutical care.23
PEER REVIEW
Peer review has been used as a quality improvement strategy in medicine and nursing.32,33 In contrast to explicit
review, which requires strict predetermined criteria that
ignore extenuating circumstances, implicit review integrates all available information about each patient.34 Researchers working in conjunction with the RAND Corporation created a structured implicit review (SIR) process
for assessing the quality of medical care delivered in the
hospital and ambulatory care settings.32 The SIR process guides the reviewer through medical records information and allows for a more consistent review of care
delivered.
A SIR process relevant to the practice of pharmaceutical care was used for this analysis based upon the
RAND SIR process. The use of SIR has been central to
Medicare quality management and for reviewing care delivered by physicians. Reviewers apply their professional expertise to provide implicit judgments about the
quality of care delivered by individual clinicians.35 Although implicit review often has high face validity, poor
interrater reliability is often a drawback. Assessments
based on medical record reviews, especially when implicit and not guided by objective criteria, can produce
disagreement among physicians on the appropriateness
and quality of care delivered to specific patients.36
The intraclass correlation coefficient (ICC) has been
used to measure interrater reliability within the implicit
review process. Six different intraclass correlation models have been delineated based on the selection of patients and reviewers, and on whether the goal is to com-
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pare individual raters with other raters or with the mean
rating of all raters.37 Coefficients above 0.75 indicate excellent agreement, those from 0.40 to 0.75 indicate fair
to good agreement, and those below 0.40 indicate poor
agreement.38
One study on the quality of medical care found that,
when using SIRs, outcome measures had higher interrater reliability than process measures.39 In pharmacy, peer
review has been applied primarily in the institutional setting as part of continuous quality improvement efforts
to evaluate, validate, and improve the appropriateness of
pharmacists’ clinical interventions.40 In this study, peer
review by physicians and pharmacists was performed to
evaluate interventions of pharmaceutical care practitioners intending to identify and resolve drug therapy problems and achieve the therapeutic goals of patients in an
ambulatory health care setting.
PROGRAM ORGANIZATION
Collaboration to provide drug therapy management services exists at 6 of the largest clinics within the Fairview
Clinics System of Minneapolis-St Paul, Minn, and more
than 3000 patients have received drug therapy management services since the program inception in 1999. There
were 3195 patients in active pharmaceutical care plans
through February 2003. Drug therapy management within
the Fairview system is defined as “a practice in which a
credentiated pharmaceutical care practitioner, working
in collaboration with physicians and other care-givers,
takes responsibility for all of a patient’s drug-related needs
and is held accountable for this commitment.”
Pharmacists complete a 120-hour, 8-week, 50patient certificate preparation program in pharmaceutical care provided by the Peters Institute of Pharmaceutical Care at the University of Minnesota. This program
represents a paradigm shift for pharmacists. It focuses on
a unique philosophy of practice and process of care, and
prepares generalist practitioners to identify, resolve, and
prevent drug therapy problems. This preparation program contrasts with continuing education programs on disease state management or certification programs by the
Board of Pharmaceutical Specialties, because the emphasis of these latter programs is on content areas or clinical
knowledge. Three pharmaceutical care practitioners in the
Fairview system hold doctorate degrees in pharmacy, 3 others hold bachelors’ degrees in pharmacy, and their total
experience as pharmacists ranges between 3 and 21 years
(mean, 12 years). Two pharmacists completed postgraduate residency programs, and 1 is a Board-Certified Pharmacotherapy Specialist.
The Fairview Credentialing Committee comprises
9 physicians and 1 pharmaceutical care practitioner who
accredit pharmaceutical care practitioners to provide care
in the Fairview system. Physicians and pharmaceutical
care practitioners use a collaborative practice agreement to enhance cooperation in the delivery of drug
therapy management services. Patients schedule pharmaceutical care appointments pursuant to physician referrals, informational mailings, self-referrals, and health
insurance company notifications. Pharmaceutical care
practitioners conduct patient assessments in a clinic ex-

amination room or in a semiprivate pharmacy consultation area.
Fairview’s pharmaceutical care practitioners assess
and document actual therapeutic outcomes at every patient encounter using a pharmaceutical care software
documentation program (Assurance Pharmaceutical Care;
licensed by the University of Minnesota, Minneapolis).
Consistent with the collaborative practice agreement, a
set of therapeutic goals are established for each of a patient’s medical conditions during the initial stage of care
plan development. These are clinical goals established in
the literature, combined with realistic, observable, and
measurable patient-specific goals. Occasionally, prescriber, pharmacist, and patient may confer to discuss patient expectations or goals of therapy.
After each encounter, a pharmaceutical care documentation note is entered into the patient’s medical record. The note includes the intended use and dose of all
active prescription and over-the-counter medications, plus
a summary of the outcome of therapy. If the patient is
experiencing a potentially harmful or urgent drug therapy
problem, the pharmaceutical care practitioners intervene immediately through consultation with the patient’s physician(s).
All patients seen in the 6 Fairview clinics affiliated
with a pharmaceutical care practitioner are eligible to receive pharmaceutical care services regardless of ability
to pay or health insurance status. Patients in the Fairview system receive these services through various research grants, demonstration projects, and third-party
payer pilot programs, or as part of a central Fairview Department of Pharmacy health system budget.
METHODS
PHARMACEUTICAL CASE SIR
A SIR process was developed as a component in the assessment of the quality improvement of Fairview’s pharmaceutical care, and to provide information on the validity of therapeutic determinations made by pharmaceutical care practitioners.
Information was obtained on the reliability of this pharmaceutical care SIR process. Validity in this analysis refers to the face
validity, or clinical credibility, of the determinations made when
collaborating to provide drug therapy management services.
Records for panel review were drawn from those of a group
of patients receiving pharmaceutical care as part of a grant designed to study the effects of providing drug therapy management services to prepaid medical assistance program (PMAP)
patients. A total of 142 PMAP patients had at least 2 visits with
a pharmaceutical care practitioner between January 1, 2000,
and December 31, 2000. The University of Minnesota’s Research Subjects Protection Program reviewed and approved this
study.
REVIEW PANEL PROCESS
Fifteen of the 142 PMAP patient records were randomly selected for peer review as case records. A 12-member peer review panel was assembled, consisting of 4 physicians with patients in pharmaceutical care plans, 4 physicians with no patients
in pharmaceutical care plans (they were practicing at a Fairview clinic that had no pharmaceutical care practitioner), and
4 pharmaceutical care practitioners. Physician panel members
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VALIDITY
Table 2. Characteristics of Patients
in Pharmaceutical Care Plans*

All Patients PMAP Patients
(N = 2524)
(n = 142)

Characteristic
No. of visits per patient,
mean
Age, range, y
Age ⱖ65 y, %
Female sex, %
No. of conditions per
patient, mean
No. of medications per
patient, mean

Peer-Reviewed
Patients
(n = 15)

2.3

2.1

2.3

3-97
48
66
6.5

18-96
38
76
6.6

32-73
20
80
6.2

8.2

7.8

8.3

RELIABILITY

Abbreviation: PMAP, prepaid medical assistance program.
*Data collected from January 1999 through March 2002.

Table 3. Characteristics of Resolved
Drug Therapy Problems*
All
PMAP
Peer-Reviewed
Patients
Patients
Patients
(N = 2524) (n = 142)
(n = 15)

Characteristic
Need for additional therapy
Dosage too low
Adherence
Adverse drug reaction
Ineffective drug therapy
Unnecessary drug therapy
Dosage too high
DTPs identified and
resolved
DTPs requiring physician
intervention, %

Each therapeutic determination was rated using a 7-point Likert
scale, with a rating of 1 corresponding to “strongly disagree”
and a rating of 7 corresponding to “strongly agree.” A Likert
rating from 5 to 7 was considered an agreement, a rating of 4
was considered a neutral opinion, and a rating of 1 to 3 was
considered a disagreement. Panelists using a rating of 1 to 4
on any item (ie, strongly disagree through neutral opinion) were
encouraged to include a comment describing the reason(s) for
their rating. When either 3 or 4 of the four panelists reviewing
a given situation agreed with the pharmaceutical care practitioners’ determination, that determination was considered valid
or clinically credible.

1720 (29)
85 (33)
1266 (22)
60 (23)
1045 (18)
34 (13)
692 (12)
33 (13)
466 (8)
19 (7)
375 (6)
17 (7)
333 (5)
11 (4)
5897 (100) 259 (100)
29

32

19 (51)
3 (8)
3 (8)
3 (8)
4 (11)
3 (8)
2 (6)
37 (100)
35

Abbreviations: DTPs, drug therapy problems; PMAP, prepaid medical
assistance program.
*Data are number (percentage) of patients unless otherwise indicated.

were selected for the review panel in consultation with the Medical Director of Fairview Clinics based on their previous experiences serving on peer review panels. Pharmaceutical care practitioners were selected based on their seniority in Fairview’s
Pharmaceutical Care Program. Each panelist evaluated 5 case
records, and each set of case records were evaluated by 4 panelists. Panelists were compensated for their time and they did
not evaluate cases in which they had provided care.
The patient case records included copies of the medical
record and pharmaceutical care chart but were devoid of any
patient, clinic, or provider identifiers. The 4 therapeutic determinations evaluated by panelists were (1) drug therapy problem determinations in the presence or absence of drug therapy
problems; (2) actions taken to resolve drug therapy problems;
(3) clinical condition status, including progress toward achieving goals of therapy; and (4) short-term cost savings estimates, if any, related to the resolution of drug therapy problems. Each line item, or situation, on the pharmaceutical care
SIR research instrument consisted of a medical condition, a medication, directions for use of the medication, and the 4 therapeutic determinations. If a patient was taking a second medication for a given medical condition, this represented a distinct
line item, or situation, on the research instrument. A situation
also included a medical condition not being treated or a treatment with no indication.

To obtain information on the reliability of the pharmaceutical
care SIR process, 3 sets of 2 patient records were selected to be
reviewed by the same 4 panelists. Patients 3 and 4 were reviewed by panelists 4, 6, 8, and 11 (set 1); patients 7 and 8 were
reviewed by panelists 1, 6, 9, and 10 (set 2); and patients 13
and 14 were reviewed by panelists 3, 5, 7, and 12 (set 3). An
ICC 3, 4 was then calculated for the 3 sets of 2 patient cases—an
ICC 3, 4 indicates (1) that patients were randomly selected, (2)
that 4 reviewers were purposively selected per patient, and (3)
that each reviewer’s scores were compared with the mean score
for all 4 reviewers who reviewed a given set of patient cases.
RESULTS

PATIENT DEMOGRAPHICS
There were 5810 documented encounters with 2524 patients in active pharmaceutical care plans from January
1999 through March 2002, or an average of 2.3 visits per
patient. The patients ranged in age from 3 to 97 years,
48% of them were older than 65 years, and 66% were
women. These 2524 patients had among them a total of
16406 medical conditions (an average of 6.5 medical conditions per patient) present at both their initial and latest pharmaceutical care encounters. They were taking,
on average, 8.2 active medications (Table 2). Demographic characteristics of the 142 PMAP patients receiving pharmaceutical care and the 15 peer-reviewed patients are also presented in Table 2.
RESOLVED DRUG THERAPY PROBLEMS
A total of 5897 drug therapy problems were identified
and resolved among the 2524 patients in Fairview’s Pharmaceutical Care Program. For a problem to be considered resolved, therapy had to be changed based on the
pharmaceutical care practitioner’s recommendation, as
evidenced by a change in the physician’s order or in the
patient’s behavior. The distribution of the 5897 resolved drug therapy problems is presented in Table 3;
71% of them were resolved without the direct involvement of the patient’s physician(s) while 29% were resolved with the active involvement of the patients’
physician(s).
A total of 259 drug therapy problems were resolved among the 142 PMAP patients enrolled in this
study, and 37 drug therapy problems were resolved in
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Table 4. Goals of Therapy Achieved Through Collaboration in Drug Therapy Management

Total No. of
Medical Conditions

Goals Met at Earliest DTM
Encounter, No. (%)

Goals Met at Latest DTM
Encounter, No. (%)

Percentage Point
Increase in Goals
Met, %

16 406 (In all 2524 patients)
937 (In the 142 PMAP patients)
93 (In the 15 peer-reviewed patients)

12 141 (74)
733 (78)
63 (68)

14 609 (89)
841 (90)
78 (84)

15
12
16

Abbreviations: DTM, drug therapy management; PMAP, prepaid medical assistance program.

the 15 peer-reviewed patients (Table 3). The 5 most frequently encountered drug therapy problems by condition in the 142 PMAP patients were in the following order:
Condition/Indication
1. Osteoporosis
2. Asthma
3. Nutritional supplementation
4. Hypertension
5. Hypothyroidism

Drug Therapy Problem
Patient needs additional drug therapy
Patient is using medication incorrectly
Patient needs additional drug therapy
Adverse drug reaction
Dosage too low

The most frequently encountered drug therapy problems by condition in the 15 peer-reviewed patients were
in the following order:
Condition/Indication
1. Diabetes
2. Hypertension
3. Asthma
4. Gastroesophageal reflux disease
5. Nutritional supplementation

Drug Therapy Problem
Patient needs additional drug therapy
Patient needs additional drug therapy
Patient is using medication incorrectly
Ineffective drug therapy
No medical indication for use

GOALS OF THERAPY ACHIEVED
At the time of the 2524 patients’ first pharmaceutical care
visit, 74% of their therapeutic goals were being met. At
the time of their final pharmaceutical care encounter, 89%
of their therapeutic goals were met (Table 4). The goals
of therapy achieved in the 142 PMAP patients and the
15 peer-reviewed patients are also presented in Table 4.
REVIEW PANEL RESULTS
The 15 patient records randomly selected for this quality assessment analysis presented a total of 300 situations. As already explained, on the research instrument
each line item, or situation, consisted of a medical condition, a medication, directions for use of the medication, and the 4 therapeutic determinations. This analysis focused on the determinations made by the
pharmaceutical care practitioner regarding each of these
situations. Among the 300 situations, 37 showed a determination of an identified drug therapy problem and
263 showed a determination that there was no drug
therapy problem present.
There were 300 situations with 4 types of determinations reviewed by 4 different panel members, resulting in a total of 4800 reviews, or clinical decision evaluations. Because the reviewers left the rating scale blank
for 21 determinations, the 12-member review panel generated 4779 clinical decision evaluations. The panelists’

ratings for 4500 of these evaluations (94.2%) agreed or
strongly agreed with the pharmaceutical care practitioners’ therapeutic outcome determinations. A neutral opinion was expressed in 172 instances (3.6%), and there were
107 instances (2.2%) in which the panelists expressed
disagreement.
Ratings were grouped to categorize the level of agreement as follows: “agree” (a rating of 5-7), “neutral” (a rating of 4), and “disagree” (a rating of 1-3). The number and
distribution of agreement scores by type of determination
made was compiled (Table 5). The level of agreement
across reviewers and situations is presented in Table 6.
A valid or clinically credible level of agreement was found
for 97.9% (1175/1200) of the situations reviewed.
Panelists provided 300 comments describing the reasons for their ratings. Of this total, 119 were general supportive comments in conjunction with agreement ratings and 93 were offered in conjunction with neutral
opinions. The panelists’ remaining 88 comments were offered in conjunction with disagreement ratings of 1 to 3
on the Likert scale. The disagreement scores and corresponding comments were fed back to the pharmaceutical care practitioners at monthly quality assurance case
presentation meetings to foster continuous quality improvement in clinical care.
RELIABILITY MEASUREMENTS
To obtain information on the reliability of this pharmaceutical care SIR process, 3 sets of 2 patient cases were
selected for review by the same 4 reviewers (ICC 3, 4).
For set 1 (patients 3 and 4 reviewed by panelists 4, 6, 8,
and 11), there was an ICC of 0.85. For set 2 (patients 7
and 8 reviewed by panelists 1, 6, 9, and 10), there was
an ICC of 0.75. For set 3 (patients 13 and 14 reviewed
by panelists 3, 5, 7, and 12), there was an ICC of 0.73.
ANALYSIS OF DRUG THERAPY PROBLEM
DETERMINATIONS
An analysis of the level of agreement related to the 37 drug
therapy problems identified in the 15 patients selected for
inclusion in this peer review analysis was conducted to obtain information on the ability of pharmaceutical care practitioners to correctly identify a drug therapy problem that
has been judged to exist. There was valid agreement for
100% (37/37) of the situations with drug therapy problems (Table 6). Unanimous agreement by all 4 panelists
was present for 28 of 37 drug therapy problem cases. In 7
of the 9 remaining cases 1 panelist expressed a neutral rat-
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Table 5. Peer Review Panel Validity Ratings of Pharmaceutical Care Practitioner Therapeutic Determinations*
% of Reviews by Rating
Therapeutic Outcome
Determinations

Reviews,
No.

Agree

Neutral

Disagree

Total†

1196
1194
1195
1194
4779

92.1
94.6
94.7
95.2
94.2

4.4
3.4
3.6
3.0
3.6

3.4
2.1
1.7
1.8
2.2

100.0
100.0
100.0
100.0
100.0

148
148
148
147
591

93.9
95.9
93.9
91.8
93.9

4.7
2.7
4.1
5.4
4.2

1.4
1.4
2.0
2.7
1.9

100.0
100.0
100.0
100.0
100.0

1048
1046
1047
1047
4188

91.9
94.4
94.8
95.7
94.2

4.4
3.4
3.5
2.7
3.5

3.7
2.2
1.6
1.6
2.3

100.0
100.0
100.0
100.0
100.0

All situations
Drug therapy problem (DTP) identification
Action to resolve problem
Condition status evaluation
Estimate of cost savings
All Determinations
Situations with DTP
DTP identification
Action to resolve problem
Condition status evaluation
Estimate of cost savings
All Determinations
Situations without DTP
Absence of DTP
Action to prevent problem
Condition status evaluation
Estimate of cost savings
All Determinations

*Validity refers to the face validity or clinical credibility of the determinations made during the collaborative practice of pharmaceutical care. Ratings were made
on a 7-point Likert scale, with 1=“strongly disagree” and 7=“strongly agree”; ratings of 1 to 3 were grouped as “disagree,” 4 as “neutral,” and 5 to 7 as “agree.”
†Of the total 4800 ratings, 21 were left blank by review panel members.

Table 6. Peer Review Panel Agreement on Validity Ratings of Pharmaceutical Care
Practitioner Therapeutic Outcome Determinations*
% of Situations Reviewed by Level of Agreement
Agreement† on Validity
Therapeutic Outcome
Determinations
All situations
Drug therapy problem (DTP)
identification
Action to resolve problem
Condition status evaluation
Estimate of cost savings
All Determinations
Situations with DTP
DTP identification
Action to resolve problem
Condition status evaluation
Estimate of cost savings
All Determinations
Situations without DTP
DTP identification
Action to resolve problem
Condition status evaluation
Estimate of cost savings
All Determinations

Nonagreement† on Validity

Situations
Reviewed, No.

All 4
Agree

3 Agree,
1 Neutral

3 Agree,
1 Disagree

Total
Agreement
Situations

2 Agree,
2 Neutral

2 Agree,
1 Neutral,
1 Disagree

Total
Nonagreement
Situations

300

72.3

11.0

13.7

97.0

1.0

2.0

3.0

300
300
300
1200

80.3
81.3
82.7
79.2

9.7
10.3
8.3
9.8

8.0
6.7
7.3
8.9

98.0
98.3
98.3
97.9

0.7
0.7
0.7
0.8

1.3
1.0
1.0
1.3

2.0
1.7
1.7
2.1

37
37
37
37
148

75.7
83.8
78.4
73.0
77.7

18.9
10.8
10.8
10.8
12.8

5.4
5.4
10.8
10.8
8.1

100.0
100.0
100.0
94.6
98.6

0.0
0.0
0.0
2.7
0.7

0.0
0.0
0.0
2.7
0.7

0.0
0.0
0.0
5.4
1.4

263
263
263
263
1052

71.9
79.8
81.7
84.0
79.4

9.9
9.5
10.3
8.0
9.4

14.8
8.4
6.1
6.8
9.0

96.6
97.7
98.1
98.8
97.8

1.1
0.8
0.8
0.4
0.8

2.3
1.5
1.1
0.8
1.4

3.4
2.3
1.9
1.2
2.2

*Validity refers to the face validity or clinical credibility of the determinations made during the collaborative practice of pharmaceutical care. Ratings were made
on a 7-point Likert scale with 1 = “strongly disagree” and 7 = “strongly agree”; ratings of 1 to 3 were grouped as “disagree,” 4 as “neutral,” and 5 to 7 as “agree.”
†Each determination was reviewed by 4 reviewers and the agreement among reviewers was considered “valid and credible” when all 4 reviewers agreed; when
3 agreed and 1 was neutral; or when 3 agreed and 1 disagreed. Disagreement was determined by fewer than 3 reviewers rating “agree.” Note that the worst case
vote was 2 agree with 1 neutral and 1 disagree. In no case was there a vote with more disagree votes than agree votes.

ing, and in the other 2 cases 1 reviewer disagreed. The 2
cases with disagreement were not related to the presence
of a drug therapy problem but with the classification of a
drug therapy problem (Table 1).

An analysis of the 263 situations determined to have
no drug therapy problems was conducted to provide information on the practitioners’ accuracy in stating that
no drug therapy problem exists (Table 6). There were
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48 instances in which 1 of 4 panelists registered a disagreement score when the pharmacist had determined
that there was no drug therapy problem. In 39 of these
48 instances, the other 3 panelists agreed with the pharmacist’s determination. There were also 9 instances where
2 reviewers were not in agreement with a determination
of no drug therapy problem. The pharmacist’s determination of the absence of a drug therapy problem was therefore considered accurate for 96.6% of the situations
(254/263).
COMMENT

The results of this study suggest that decisions made by
pharmaceutical care practitioners working in collaboration with physicians and other caregivers to provide drug
therapy management services are clinically credible. The
collaborative practice of pharmaceutical care may help to
reduce drug-related morbidity and improve therapeutic outcomes by optimizing responsiveness to patient needs in
their use of medication. Causes of suboptimal medication use outcomes include acts of commission, unpredictable events, and the absence of pharmaceutical care systems. The presence of a pharmaceutical care practitioner
who is responsible for applying a systematic problemsolving process to the use of all of a patient’s medications
can consistently ensure that the patients’ drug-related needs
are met.
Recent studies and reviews suggest that pharmacists’ interventions can improve patient outcomes, reduce health expenditures, and prevent errors. The impact of pharmacists’ contributions in drug therapy decision
making is found in the literature evaluating the effectiveness of clinical pharmacy services. Compared with
studies of pharmacists’ performance in clinical decision
making, this study provides information relating to the
face validity or clinical credibility of collaborative drug
therapy management services.
Although there are indications that the pharmaceutical care SIR process used in this analysis is reliable using the ICC in a subset of common patient cases, additional studies would help to corroborate these findings.
This was discovery work, conducted to identify trends
and patterns of agreement with pharmaceutical care practitioners’ therapeutic determinations using an implicit review process. Further studies in this area could be designed to have all panelists review the same patient cases
to test the reliability of rater measurements and compare ratings between individual panelists.
The main responsibilities of pharmaceutical care
practitioners are to identify, resolve, and prevent drug
therapy problems that impede progress toward achieving intended therapeutic goals. A quality improvement
analysis of drug therapy problem determinations was conducted to obtain information on practitioners’ abilities
to identify a drug therapy problem when one is judged
to exist, and to accurately state that no drug therapy problem exists. This analysis revealed estimates of 100% accuracy in identifying drug therapy problems and 97% in
determining the absence of drug therapy problems.
Documenting patients’ actual therapeutic outcomes represents a desirable activity in any health care

system. Therapeutic goals achieved increased from 74%
at the time of patients’ initial pharmaceutical care encounters to 89% at their latest encounters. This study provides data demonstrating the clinical credibility of the
therapeutic outcome determinations of pharmaceutical
care practitioners when they collaborate with physicians to provide drug therapy management services.
Patients, health care providers, employers, third-party payers, and policymakers can use these data to make betterinformed decisions about the value and role of collaboration in reducing drug-related morbidity and achieving
therapeutic goals.
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Correction
Incorrect Name Order. In the Commentary by Goodnough et al titled “Anemia: Not Just an Innocent Bystander?” published in the June 23 issue of the
ARCHIVES (2003;163:1400-1404), the authors should have appeared in the following order in the signature block on page 1403: Lawrence T. Goodnough
MD; Robert W. Dubois, MD, PhD; and Allen R. Nissenson, MD. The journal
regrets the error.
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